Retrospective Study
Copyright ©The Author(s) 2021.
World J Hepatol. Mar 27, 2021; 13(3): 362-374
Published online Mar 27, 2021. doi: 10.4254/wjh.v13.i3.362
Table 3 Univariate and multivariate analysis of factors associated with patient mortality

Univariate analysis
Multivariate analysis1
P valueHR (95%CI)P valueHR (95%CI)
Age of donor ≥ 70 years0.550.73 (0.26-2.05)
Recipient
Liver steatosis 0.10.408 (0.09-1.79)
Age ≥ 60 years0.941.04 (0.39-2.78)
HCV infection as cause of liver disease0.023.02 (1.17-7.81)0.0034.94 (1.72-14.17)
Presence of hepatocellular carcinoma0.571.31 (0.52-3.34)
MELD score ≥ 20 0.023.16 (1.12-8.91)0.0036.06 (1.88-19.56)
Diabetes before transplantation0.631.32(0.43-4.01)
Hypertension before transplantation0.052.78 (0.98-7.90)--
MDRD-4 at baseline0.350.99 (0.97-1.01)
Mycophenolate mofetil at initial therapy0.891.07 (0.38-3.02)
Outcomes and complications
BPAR0.202.08 (0.67-6.43)
Arterial complications0.062.91 (0.94-9.06)0.033.76 (1.12-12.62)
Biliary complications0.591.41 (0.40-4.92)
Renal dysfunction early after transplant20.082.40 (0.90-6.38)--
Renal hypertension0.821.12 (0.42-3.02)
De novo diabetes0.023.25 (1.24-8.55)--
Cardiovascular0.14
Arterial hypertension0.080.32 (0.09-1.15)--
Heart failure0.260.31 (0.04-2.37)
De novo tumor0.0054.20 (1.56-11.32)< 0.00113.82 (4.06-46.98)
HCV recurrence0.221.79 (0.70-4.53)
HCC recurrence0.00816.61 (2.10-131.07)--
Any infection0.711.12 (0.47-3.03)
Bacterial infection0.042.71 (1.04-7.07)--
Viral infection0.390.61 (0.20-1.87)
Fungal infection0.871.19 (0.16-9.03)
Cytomegalovirus infection0.790.86 (0.28-2.62)
Normal renal function at last visit (MDRD-4 ≥ 60 mL/min/1.73 m2)0.921.08 (0.23-5.08)
Mean tacrolimus levels at days 1-30 after LT
> 10 ng/mL vs ≤ 10 ng/mL0.441.44 (0.57-3.65)
< 7 ng/mL (reference)30.32
7-10 ng/mL0.310.49 (0.12-1.96)
> 10 ng/mL0.591.33 (0.47-3.73)
> 8 ng/mL vs < 8 ng/mL30.781.14 (0.44-2.95)
Early graft dysfunction0.082.44 (0.890-6.63)< 0.0016.02 (2.34-15.49)